他汀类药物对慢性肝脏疾病进展及预后的影响

王帅; 张永贵; 王江滨; 徐严

doi:10.3969/j.issn.1001-5256.2021.03.045

他汀类药物对慢性肝脏疾病进展及预后的影响

DOI: 10.3969/j.issn.1001-5256.2021.03.045

吉林大学中日联谊医院消化内科，长春 130033

基金项目:

国家自然科学基金 (81670533);

吉林省教育厅资助项目 (JJKH20190067KJ)

利益冲突声明: 所有作者均声明不存在利益冲突。

作者贡献声明：王帅、张永贵负责收集资料，撰写论文；王江滨、徐严负责对文章的知识性内容作批评性审阅，指导撰写文章并最后定稿。

详细信息

作者简介:
王帅(1995—)，男，主要从事肝脏疾病方面的研究

通信作者:
徐严，saltyan_1115@jlu.edu.cn

中图分类号: R575
计量
- 文章访问数: 449
- HTML全文浏览量: 137
- PDF下载量: 68
- 被引次数: 0
出版历程
- 收稿日期: 2020-08-11
- 录用日期: 2020-10-12
- 出版日期: 2021-03-20

Effect of statins on the progression and prognosis of chronic liver diseases

Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun 130033, China

摘要

摘要: 慢性肝病严重时可进展为肝纤维化和肝硬化，进而引起门静脉高压，最终可能发展至肝细胞癌。近年来，越来越多的研究发现他汀类药物可以使非酒精性脂肪性肝病患者的肝脏组织学得到改善，延缓肝纤维化进展，降低失代偿事件以及肝细胞癌的发生风险。介绍了他汀类药物在慢性肝病患者中的应用进展，为慢性肝脏疾病的防治提供一定的依据。
- 肝疾病 /
- 羟甲基戊二酰基CoA还原酶抑制剂 /
- 治疗结果 /
- 预后
Abstract: Chronic liver diseases can progress to liver fibrosis and cirrhosis and may lead to portal hypertension and even hepatocellular carcinoma. In recent years, more and more studies have shown that statins can improve liver histology, delay progression to liver fibrosis, and reduce the risk of decompensation and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. This article introduces the advances in the application of statins in patients with chronic liver diseases, so as to provide a basis for the prevention and treatment of chronic liver diseases.
- Liver Diseases /
- Hydroxymethylglutaryl-CoA Reductase Inhibitors /
- Treatment Outcome /
- Prognosis

HTML全文

参考文献(28)

[1]	STONE NJ, ROBINSON JG, LICHTENSTEIN AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2889-2934.
[2]	PASTORI D, POLIMENI L, BARATTA F, et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease[J]. Dig Liver Dis, 2015, 47(1): 4-11. DOI: 10.1016/j.dld.2014.07.170
[3]	TSOCHATZIS EA, BOSCH J. Statins in cirrhosis-Ready for prime time[J]. Hepatology, 2017, 66(3): 697-699. DOI: 10.1002/hep.29277
[4]	GOLDSTEIN JL, BROWN MS. A century of cholesterol and coronaries: From plaques to genes to statins[J]. Cell, 2015, 161(1): 161-172. DOI: 10.1016/j.cell.2015.01.036
[5]	VARGAS JI, ARRESE M, SHAH VH, et al. Use of statins in patients with chronic liver disease and cirrhosis: Current views and prospects[J]. Curr Gastroenterol Rep, 2017, 19(9): 43. DOI: 10.1007/s11894-017-0584-7
[6]	DOUMAS M, IMPRIALOS K, DIMAKOPOULOU A, et al. The role of statins in the management of nonalcoholic fatty liver disease[J]. Curr Pharm Des, 2018, 24(38): 4587-4592.
[7]	ATHYROS VG, BOUTARI C, STAVROPOULOS K, et al. Statins: An under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk[J]. Curr Vasc Pharmacol, 2018, 16(3): 246-253. DOI: 10.2174/1570161115666170621082910
[8]	CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367
[9]	TREBICKA J, HENNENBERG M, ODENTHAL M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells[J]. J Hepatol, 2010, 53(4): 702-712. DOI: 10.1016/j.jhep.2010.04.025
[10]	MARRONE G, RUSSO L, ROSADO E, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins[J]. J Hepatol, 2013, 58(1): 98-103.
[11]	KUMAR S, GRACE ND, QAMAR AA. Statin use in patients with cirrhosis: A retrospective cohort study[J]. Dig Dis Sci, 2014, 59(8): 1958-1965. DOI: 10.1007/s10620-014-3179-2
[12]	CHANG FM, WANG YP, LANG HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study[J]. Hepatology, 2017, 66(3): 896-907. DOI: 10.1002/hep.29172
[13]	MOHANTY A, TATE JP, GARCIA-TSAO G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis[J]. Gastroenterology, 2016, 150(2): 430-440. DOI: 10.1053/j.gastro.2015.10.007
[14]	DONGIOVANNI P, PETTA S, MANNISTO V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals[J]. J Hepatol, 2015, 63(3): 705-712. DOI: 10.1016/j.jhep.2015.05.006
[15]	NASCIMBENI F, ARON-WISNEWSKY J, PAIS R, et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease[J]. BMJ Open Gastroenterol, 2016, 3(1): e000075. DOI: 10.1136/bmjgast-2015-000075
[16]	TREBICKA J, SCHIERWAGEN R. Statins, Rho GTPases and KLF2: New mechanistic insight into liver fibrosis and portal hypertension[J]. Gut, 2015, 64(9): 1349-1350. DOI: 10.1136/gutjnl-2014-308800
[17]	ABRALDES JG, ALBILLOS A, BAÑARES R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial[J]. Gastroenterology, 2009, 136(5): 1651-1658. DOI: 10.1053/j.gastro.2009.01.043
[18]	POLLO-FLORES P, SOLDAN M, SANTOS UC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial[J]. Dig Liver Dis, 2015, 47(11): 957-963. DOI: 10.1016/j.dld.2015.07.156
[19]	ABRALDES JG, VILLANUEVA C, ARACIL C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis[J]. Gastroenterology, 2016, 150(5): 1160-1170. DOI: 10.1053/j.gastro.2016.01.004
[20]	FUJIWARA D, TSUBAKI M, TAKEDA T, et al. Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells[J]. Tumour Biol, 2017, 39(10): 1010428317734947.
[21]	YOKOHAMA K, FUKUNISHI S, Ⅱ M, et al. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice[J]. Int J Mol Med, 2016, 38(5): 1499-1506. DOI: 10.3892/ijmm.2016.2766
[22]	SINGH S, SINGH PP, SINGH AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis[J]. Gastroenterology, 2013, 144(2): 323-332. DOI: 10.1053/j.gastro.2012.10.005
[23]	SHI M, ZHENG H, NIE B, et al. Statin use and risk of liver cancer: An update meta-analysis[J]. BMJ Open, 2014, 4(9): e005399. DOI: 10.1136/bmjopen-2014-005399
[24]	KIM G, JANG SY, NAM CM, et al. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study[J]. J Hepatol, 2018, 68(3): 476-484. DOI: 10.1016/j.jhep.2017.10.018
[25]	NISHIO T, TAURA K, NAKAMURA N, et al. Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: A subgroup analysis of patients without chronic hepatitis viral infection[J]. Surgery, 2018, 163(2): 264-269. DOI: 10.1016/j.surg.2017.09.026
[26]	LAW M, RUDNICKA AR. Statin safety: A systematic review[J]. Am J Cardiol, 2006, 97(8A): 52C-60C.
[27]	PFEFFER MA, KEECH A, SACKS FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project[J]. Circulation, 2002, 105(20): 2341-2346. DOI: 10.1161/01.CIR.0000017634.00171.24
[28]	BISHNU S, AHAMMED SM, SARKAR A, et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: A proof-of-concept study[J]. Eur J Gastroenterol Hepatol, 2018, 30(1): 54-59. DOI: 10.1097/MEG.0000000000001006